Researchers examined the association between childhood Risky Family (RF) environment and cardiovascular health (CVH).
Adding Atezolizumab Improves Survival in Advanced Cervical Cancer
First-line treatment with the anti-PD-L1 inhibitor atezolizumab (Tecentriq) combined with bevacizumab (Avastin) and platinum-based chemotherapy significantly improved survival in patients with metastatic or recurrent cervical